RESEARCH MONOGRAPH · KDC-MN-242
Sodium Valproate
Sodium valproate (Depakote, in the divalproex form) is a deceptively simple molecule (a branched fatty acid) that turned out to do an extraordinary number of useful things in the brain: block voltage-gated sodium channels, raise GABA levels by inhibiting GABA transaminase, block T-type calcium channels, and inhibit histone deacetylases. Originally noticed in 1962 as a bioactive compound while serving as a solvent in pharmacology screening, it was approved by the FDA in 1978 and remains a first-line anticonvulsant for generalized seizures, one of the two best mood stabilizers in bipolar disorder, and a workhorse for migraine prevention. It is highly teratogenic (causes severe birth defects) and women of childbearing potential should generally avoid it. Liver toxicity, pancreatitis, and weight gain are notable. Not stocked by Kodiac. This monograph is provided for research and educational reference.
Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.
Branched-chain fatty acid anticonvulsant / mood stabilizer
A simple branched-chain fatty acid with broad anticonvulsant activity and mood-stabilizing efficacy in bipolar disorder.
Abstract
Sodium valproate (sodium 2-propylpentanoate; CAS 1069-66-5; molecular formula C8H15NaO2; molecular weight 166.20) is a branched-chain fatty acid anticonvulsant first characterized as bioactive in 1962 (incidentally, while serving as a solvent in pharmacological screening at Lyon). Approved by the FDA in 1978 (Depakote, the divalproex sodium delayed-release form). Mechanism is multifactorial: GABA transaminase inhibition increases brain GABA; sodium channel blockade reduces neuronal hyperexcitability; T-type calcium channel inhibition supports anti-absence activity; histone deacetylase (HDAC) inhibition modifies gene expression with neuroprotective and possibly disease-modifying implications in bipolar disorder. Plasma half-life is 9 to 16 hours; metabolism is via beta-oxidation, omega-oxidation, and glucuronidation. Approved indications include all major seizure types (partial, generalized tonic-clonic, absence, myoclonic), bipolar I disorder mania, and migraine prophylaxis. The principal limitation is teratogenicity (neural tube defects, cognitive deficits in offspring) requiring strict avoidance in pregnancy and women of childbearing age. Hepatotoxicity, pancreatitis, and hyperammonemia are recognized adverse events. Used as the canonical broad-spectrum anticonvulsant and HDAC inhibitor reference.
Mechanism of action
Multifactorial: GABA transaminase inhibition, sodium and T-type calcium channel block, HDAC inhibition. Broad anticonvulsant activity and mood stabilization.
Reported research dose ranges
Clinical 750 to 3000 mg per oral administration daily. Rodent studies 100 to 600 mg/kg/day.
References
- Loscher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 2002.
- Bowden CL, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 1994.
- Phiel CJ, et al. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001.
Read the full monograph
The full reference document is available below as a PDF embed and download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.